CytomX Therapeutics (CTMX) Cash from Operations Growth (3y) (2017 - 2026)

CytomX Therapeutics (CTMX) Cash from Operations Growth (3y) (2017 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Ops. Growth (3y) (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -5.07%
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 33.08%
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 16.64%
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn -7.60%
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn -
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 CytomX Therapeutics 590.32 Mn 243.61 Mn - -67.90%

Historic Data

Download Data
DateValue
Mar 31, 2026 -67.90%
Dec 31, 2025 -155.53%
Sep 30, 2025 22.84%
Jun 30, 2025 22.80%
Mar 31, 2025 20.14%
Dec 31, 2024 13.90%
Sep 30, 2024 11.30%
Jun 30, 2024 11.50%
Mar 31, 2024 4.54%
Dec 31, 2023 -8.02%
Sep 30, 2023 9.58%
Jun 30, 2023 -31.22%
Mar 31, 2023 29.82%
Dec 31, 2022 63.85%
Sep 30, 2022 -13.22%
Jun 30, 2022 11.05%
Mar 31, 2022 -1.91%
Dec 31, 2021 -2.76%
Sep 30, 2021 -74.90%
Jun 30, 2021 -1.94%